STAA logo

STAAR SURGICAL CO

STAANASDAQ
πŸ† #2464 by market capUS Equity
$22.69β–² $1.95 (+8.59%)
Live
πŸ””
Track STAA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 8.6%
7dβ–² 10.0%
14dβ–² 1.1%
30dβ–² 2.7%
ytdβ–Ό 1.7%
1yβ–Ό 15.5%
🏦Market Cap
$1.13B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-23.7%
Declining
πŸ“ŠGross Margin
76.2%
High
πŸ’΅FCF Margin
-2.0%
Thin
βš–οΈP/S Ratio
3.0x
Fair
Otter Score
76
Good

Trading Snapshot

Day Range
$22.46 – $22.87
52-Week Range
$15.59 – $35.87
Volume
$2.93B
Avg Volume
$3.03B
Shares Outstanding
49.8M
Next Earnings
Dec 2, 2026

Fundamentals Snapshot

Annual Revenue
$239M
Last Q Revenue
$94M
P/E Ratio
256.4
P/S Ratio
3.0x
EPS (TTM)
$0.08
Dividend Yield
0.00%
Dilution (1yr)
+4.0%

Why Investors Own STAA

  • βœ“High-growth profile β€” revenue up +50.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 43% gross margin and 25% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

STAA logo

STAAR SURGICAL CO

STAA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$239Mβ–Ό βˆ’23.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
76.2%β–Ό βˆ’0.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$46Mβ–² +264.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$40Mβ–² +422.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
51.5Mβ–² +4.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$113Mβ–Ό βˆ’$24M YoY
StockOtter Β· stockotter.space

About STAAR SURGICAL CO

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Price Target

β“˜
Average Target
$25.00
β–² +10.2% Upside
High Target$31.10
Low Target$23.29
Based on 20 analysts

Latest News & Updates